Panobinostat is an oral medication used to treat multiple myeloma. It is a type of histone deacetylase inhibitor (HDACi), which helps to reduce the growth of cancer cells. Panobinostat works by blocking the activity of certain proteins that control the activity of genes involved in cell growth and division. This helps to slow down or stop the growth of cancer cells. Panobinostat is usually used in combination with other medications to treat multiple myeloma. Side effects may include nausea, fatigue, diarrhea, and constipation.
Panobinostat, previously sold under the brand name Farydak, was a medication used in specific cases of multiple myeloma, a cancer of the blood plasma cells [1, 2]. However, it's important to note that Panobinostat was withdrawn from the market in the United States in March 2022 [2].
Here's what you should know about Panobinostat:
- Type of drug: Panobinostat is classified as a histone deacetylase (HDAC) inhibitor [1]. HDAC inhibitors are a type of chemotherapy medication.
- How it worked: Panobinostat worked by affecting proteins called histones, which are involved in packaging DNA within cells. By inhibiting these proteins, Panobinostat could potentially slow or stop the growth of cancer cells [3].
- Uses: Panobinostat was used in combination with other medications, specifically bortezomib and dexamethasone, to treat adults with multiple myeloma who had already undergone at least two prior treatment regimens [2].
- Administration: Panobinostat was given in capsule form taken by mouth [4].